
A. Cheraghvandi,1 L. Fadaizadeh,2 S.A. Taheri3 and M.R. Masjedi4

ABSTRACT While airways reactivity is among the characteristics of asthma, it is not considered a sufficient condition diagnostically and the methacholine challenge is a non-specific diagnostic aid in cases of chronic cough and reactive airways disease. The aim of this cross-sectional study was to determine the metacholine response positivity and diagnosis of asthma in patients with chronic cough presenting to a hospital in Tehran during 2007 and 2008. Of 101 patients with chronic cough (with no history of sinusitis, recent pulmonary infection, bronchitis, gastroesophageal reflux or underlying pulmonary conditions), 51.5% showed reactive airways disease to the methacholine test, 40.6% were unreactive and 7.9% were indeterminate. A positive methacholine challenge test was positively correlated with new wheezing. Although the methacholine challenge test is not a primary test for evaluating chronic cough, if no other reason for chronic cough is found, it may be a guiding test for asthma.

1Lung Transplantation Research Centre; 2Telemedicine Research Centre; 3Clinical Tuberculosis and Epidemiology Research Centre; 4Chronic Respiratory Diseases Research Centre, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran (Correspondence to A. Cheraghvandi: cheraghvandiali@yahoo.com).

Received: 21/12/11; accepted: 21/02/12
Introduction

One of the characteristics of most asthmatic patients is cough and increased airways responsiveness on exposure to selected allergens. Yes, while airways reactivity is among the characteristics of asthma, it is not considered a sufficient condition diagnostically. It is also not clear which comes first, control of bronchial diameter or hyper-reactivity [1].

The methacholine challenge test is a non-specific diagnostic aid in cases of chronic cough and reactive airways disease. In a report by Wongtim et al. the methacholine test was shown to have an important role in reaching a diagnosis in patients with chronic cough and its positive predictive value for asthma was 60%–82% [2]. In another large study in Australia with 876 participants, 81% had hyper-reactiveness to inhaled histamine while only 6% were diagnosed with asthma based on reactivity of the airways [3]. In a similar study of airways reactivity linked to various occupations it was demonstrated that hyper-reactivity was much more common than what could be medically termed asthma [4,5]. It seems therefore that airways hyper-reactivity is only one part of asthma and can also be a cause of chronic cough. As a result, it is prudent to look for other reasons for airways reactivity and not attribute it only to asthma. Specific and non-specific tests can be helpful in this endeavour. Studies concerning cough and asthma are few and we planned this study to determine the prevalence of asthma among patients with symptoms of cough who had an extensive work-up for this condition. Patients in whom a definite diagnosis using clinical symptoms or spirometry results could not be reached were invited to participate in the methacholine challenge test.

Methods

Sample

This was a cross-sectional study of patients with chronic cough during the years 2007 and 2008. All patients over the 2-year period who presented with chronic cough and who met the inclusion criteria were included in the study. The inclusion criteria were chronic cough of more than 3 weeks duration, cough without a known cause, age above 10 years and normal radiography of the chest, sinuses and spirometry. Exclusion criteria were all patients with asthma, pulmonary infections, gastroesophageal reflux, foreign body aspiration, recent upper respiratory infections (within 8 weeks), chronic bronchitis, sinusitis or other pulmonary conditions or symptoms consistent with airways disease such as wheezing.

Data collection

Patients were advised not to take methacholine, theophylline, antihistamines, β-agonists, sympathomimetics or anticholinergic medications for 48 hours before the test. The methacholine test was performed according to the following pulmonary laboratory protocol.

A spirometry test was performed and if the patient’s forced expiratory volume in 1 sec (FEV1) was above 70% of expected, saline nebulizer treatment was given for 2 minutes. After 3 minutes rest the patient underwent a spirometry test. If FEV1 did not drop by 20%, treatment with methacholine was started. The first concentration of the methacholine nebulizer was 0.03 mg/mL for 2 minutes, after which 3 minutes of rest was given and spirometry was performed again. If there was no drop in FEV1 below 20%, testing was continued with double doses of methacholine until one of these occurred: a drop in FEV1 20% below the first FEV1 or a dose of 16 mg/mL methacholine was reached. If a patient developed coughing, shortness of breath or wheezing, the test was ended and considered positive.

A drop in FEV1 of 20% was considered positive for airways hyper-reactivity, 16% was considered negative and between 16%–20% was considered indeterminate and the test was repeated after 2 weeks.

Data analysis

Information from the patient’s history, physical examination and the methacholine test results were analysed statistically using the chi-squared test. Statistical analysis was done using SPSS, version 9.

Results

A total of 101 participants met the inclusion criteria (51 men and 50 women), with a mean age of 38.8 [standard deviation (SD) 15.4] years, range 14–74 years.

All patients had a history of cough of more than 3 weeks. Other clinical symptoms, summarized in Figure 1, showed that 61.4% had shortness of breath, 52.5% had paroxysmal nocturnal dyspnoea and 48.5% had sputum production. Of the total patients 9.9% were smokers but none reported being substance abusers. At study entry none of them had other pulmonary diseases, sinusitis, recent cold (past 8 weeks) and wheezing on auscultation. In their past medical history 32 individuals (31.7%) reporting having had sinusitis, 9.9% eczema and 4.0% acute bronchitis.

The final results of the methacholine challenge test showed 52 cases were positive (51.5%), 8 were indeterminate (7.9%) and 41 were negative (40.6%). The rate of airways reactivity was higher among women (58.0%) compared with men (45.1%) but this was not statistically significant (Table 1). The mean methacholine concentration in the nebulizer that gave positive test results was 7.8 (SD 6.9) mg/mL, range 0.06 to 16 mg/mL. Of the individuals with a positive test, 42/52 (80.8%) had a 20% decrease in FEV1, 9 (17.3%) had wheezing and 1 (1.9%) developed severe coughing and the test was discontinued. Patients with positive tests were prescribed bronchodilators. Of the 8
Discussion

In this study 101 participants with chronic cough underwent the methacholine challenge test. The results showed that 52 (51.5%) of them had airways hyper-reactivity to the test, which is comparable to the results from similar studies [6–9]. Patients with chronic cough may show hyper-reactivity significant enough to undergo more complete evaluation. The average dose of methacholine that led to positive test was 7.8 (SD 6.9) mg/mL, which is similar to these other studies. A positive methacholine test at doses < 8 mg/mL (proactive concentration) may therefore be a good marker for diagnosis of asthma [1].

The rate of airways reactivity was higher in women than men (58.0% versus 45.1%) but this was not statistically significant. While a similar result has been found in some studies [10–13], other studies do not support this finding [14,15].

In this study, only a positive methacholine challenge test had a positive correlation with wheezing, which could be a sign of airways hyper-reactivity that is not seen with other symptoms. Individuals with sinusitis, eczema and acute bronchitis did not show a positive methacholine challenge test and a history of such conditions may not influence airways hyper-reactivity.

During the methacholine challenge test, the average drop in FEV1 for positive tests for these patients was 21.4 (SD 8.7) L, and the increase after bronchodilator administration was 15.7 (SD 9.5) L, which can be a sign of bronchial asthma [1]. A 16% improvement in FEV1 using a bronchodilator is an indicator of effective therapeutic response.

In conclusion, even though the methacholine challenge test is not a primary test for evaluating chronic cough it may be a guiding test for asthma, if no other reason for chronic cough is found.

Acknowledgements

The authors would like to thank all colleagues at Masih Daneshvari Hospital who helped with the preparation of this manuscript.

Competing interests: None declared.
References